<DOC>
	<DOCNO>NCT02424942</DOCNO>
	<brief_summary>Primary Objective : To assess safety tolerability ascend single intraarticular dos GZ389988 patient painful osteoarthritis ( OA ) knee . Secondary Objectives : To assess pharmacokinetic ( PK ) parameter ascend single intraarticular dos GZ389988 patient painful OA knee . To obtain preliminary pharmacodynamic evaluation ascend single intraarticular dos GZ389988 patient painful OA knee .</brief_summary>
	<brief_title>First-in-human Study With Ascending Single Intra-articular Doses GZ389988 Patients With Painful Osteoarthritis Knee</brief_title>
	<detailed_description>Screening perform within 28 day dose . Following single dose study medication , study period patient 84 ± 7 day end-of-study visit . Total duration one patient 17 week ( end-of-study visit ) , include long term observational safety follow-up phone call 12 additional week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Inclusion criterion : Men woman 40 60 year age . Diagnosis primary knee osteoarthritis , base upon follow : Fulfilling American College Rheumatology Clinical Radiographic criterion OA ( least knee pain osteophyte ) , Xray evidence within last 6 month Kellgren Lawrence classification II IV . Western Ontario McMaster Universities Arthritis Index ( WOMAC ) A1 Pain subscore ( walk pain ) 50 90 use 100mm visual analog scale ( VAS ) , correspond moderate severe pain index knee , screen baseline assessment least 48 hour apart . Symptomatic 6 month ( symptomatic knee , least painful knee receive study drug ) . Having give write informed consent prior procedure relate study . Ambulatory active lifestyle good general health . ( Assistive device allow use throughout period 3 month prior screen , condition continue use throughout study ) . A male sexually active must use condom part method highly effective contraception ( eg , condom + spermicide , additional contraceptive method use partner ) sexual intercourse woman childbearing potential duration study period endofstudy visit father child period . Male patient also agree donate sperm duration study endofstudy visit . Exclusion criterion : Women childbearing potential . Pregnant breastfeed woman . Any uncontrolled , chronic condition laboratory finding , opinion Investigator , could potentially put patient increase risk . Patients clinically significant uncontrolled hepatic , gastrointestinal , cardiovascular , respiratory , neurological ( include diabetic neuropathy ) , psychiatric , hematological , renal , dermatological disease , medical condition might interfere evaluation investigational medicinal product ( IMP ) accord Investigator 's medical judgment . Chondrocalcinosis . Fibromyalgia . Major depression . History presence drug alcohol abuse ( alcohol consumption &gt; 40 gram per day ) . Any patient , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development . Abnormal coagulation parameter : outside range international normalize ratio ( INR ) 0.851.15 , activate partial thromboplastin time &gt; 33 second , platelet &lt; 140 x 10^9/L . Moderate severe renal impairment . Underlying hepatobiliary disease and/or alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal ( ULN ) . High sensitivity Creactive protein ( hsCRP ) &gt; 2 x ULN . Hemoglobin &lt; 10 g/dL , white blood cell count ( WBC ) &lt; 3 x 10^9/L . Positive result follow test : hepatitis B surface ( HBsAg ) antigen , antihepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 antiHIV2 Ab ) . Secondary OA . Ipsilateral hip OA . Symptomatic contralateral knee OA WOMAC A1 pain subscore ( walk pain ) &gt; 30 100mm VAS . Prior history osteonecrosis and/or rapidly progressive OA . Intraarticular injection within 3 month prior inclusion . Unable maintain least 2 week prior entry study paracetamol ( No nonsteroidal noninflammatory drug [ NSAID ] use 12 week study ; endofstudy visit [ Day 84 ± 7 ] patient may give NSAID necessary provide good control OA symptom ) . Any IMP within 3 month prior study . Any knee MRI contraindication . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>